A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Completed · Phase 3 · Has a placebo group

Conditions studied: Psoriasis

In brief

The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.

Key facts

Study ID

NCT01550744

Run by

Janssen Biotech, Inc.

People needed

478

Starts

2012-03-01

Expected to finish

2015-07-01

Last updated by the study team

2017-02-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Bakersfield, California, United States
• Study site — Irvine, California, United States
• Study site — Los Angeles, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — Santa Monica, California, United States
• Study site — Denver, Colorado, United States
• Study site — Bridgeport, Connecticut, United States
• Study site — Coral Gables, Florida, United States
• Study site — Saint Augustine, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Plainfield, Indiana, United States
• Study site — Louisville, Kentucky, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Boston, Massachusetts, United States
• Study site — Troy, Michigan, United States
• Study site — Fridley, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — Henderson, Nevada, United States
• Study site — Lebanon, New Hampshire, United States
• Study site — East Windsor, New Jersey, United States
• Study site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.